

brinzolamide 10mg/mL eye drops (Azopt®) (No: 546/09)
Alcon Laboratories (UK) Limited

Product Update

06 March 2009

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

brinzolamide (Azopt®) eye drops are accepted for use within NHS Scotland to decrease elevated intraocular pressure in ocular hypertension and open-angle glaucoma as monotherapy in patients unresponsive to beta-blockers or in patients in whom beta-blockers are contraindicated, or as adjunctive therapy to beta-blockers or prostaglandin analogues.

This abbreviated submission relates to a licence extension to cover use of brinzolamide with prostaglandin analogues. For patients in whom brinzolamide is an appropriate choice of therapy, this licence extension is not associated with a price increase and is not expected to increase drug usage.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 13 January 2009.

**Chairman,
Scottish Medicines Consortium**

Published 14 April 2009